Sirolimus + Bispecific Antibodies for Multiple Myeloma

This trial explores a new treatment approach for people with multiple myeloma, a type of blood cancer. It aims to determine if pre-treating with sirolimus (a medicine that affects the immune system) before using bispecific antibodies (which help the immune system target cancer cells) is safe and effective. The bispecific antibodies under study include talquetamab and teclistamab. The study seeks participants diagnosed with multiple myeloma who have previously tried certain T-cell therapies. Those with experience in these treatments and a stable condition may be a good fit for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

You may need to stop taking certain medications before joining the trial. Specifically, you cannot take corticosteroids, certain immune system drugs, or investigational drugs close to the start of the trial. If you're on an ACE-inhibitor, you might need to switch to a different type of medication.

In a previous study, teclistamab, when combined with other drugs, demonstrated a manageable safety profile. Patients with multiple myeloma tolerated the treatment well, with common side effects being mild. Another study confirmed teclistamab's approval for other treatments, supporting its safety record.

Research found that talquetamab was generally well-tolerated when used alone or with other treatments. The most common side effect was cytokine release syndrome (CRS), occurring in about 76% of patients. CRS can cause fever and tiredness, but it was usually mild.

Sirolimus, used as a pre-conditioning treatment, has been studied for its effects on immune cells. While specific safety data isn't provided here, its use alongside approved treatments like teclistamab suggests reasonable safety.

Researchers are excited about this treatment for multiple myeloma because it combines sirolimus, an immunosuppressant, with bispecific antibodies like teclistamab and talquetamab. Unlike standard treatments such as proteasome inhibitors or immunomodulatory drugs, this combination aims to enhance the immune system's ability to fight cancer by pre-conditioning patients with sirolimus. This approach could potentially improve the effectiveness of bispecific antibodies, which are designed to engage two different targets, increasing the precision and power of attacking myeloma cells. By exploring this novel mechanism of action, researchers hope to offer a more effective treatment option for patients with multiple myeloma.

This trial will evaluate the combination of Sirolimus with either teclistamab or talquetamab for treating multiple myeloma. Research has shown that using talquetamab and teclistamab together holds promise for treating this type of blood cancer. In one study, about 86.6% of patients responded to this combination, with nearly 96.3% showing positive results at the recommended dose. Most patients experienced a reduction in cancer symptoms. In this trial, Sirolimus will be administered before either teclistamab or talquetamab to potentially enhance their effectiveness by preparing the immune system. Together, these treatments aim to improve outcomes for people facing challenging cases of multiple myeloma.²³⁴⁶⁷